MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study

Intracranial Aneurysm Clinical Trial

Official title:

MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05409989
• Other study ID #: CL11023
• Status: Recruiting
• Phase: N/A
• Start date: September 20, 2022
• Est. completion date: November 2029

Study information

• Verified date: April 2024
• Source: Microvention-Terumo, Inc.
• Contact: Amy Bowles
• Phone: 678-858-0992
• Email: Amy.bowles[@]microvention.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to generate contemporaneous clinical data to facilitate a reasonable comparison of the performance of the FRED™ X™ device with the performance of the FRED™ device. The data generated from this study will be compared to the safety and effectiveness of the FRED™ device by meeting the same performance goals (PGs) established for the FRED™ pivotal study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 154
• Est. completion date: November 2029
• Est. primary completion date: September 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: 22 Years to 75 Years

Eligibility

Inclusion Criteria:

Subjects for this study must meet ALL the following criteria:

1. Subject has single target aneurysm in the internal carotid artery from petrous segment to the terminus of the internal carotid artery.

2. The parent artery diameter must be 2.0 - 5.0 mm distal and/or proximal to the target intracranial aneurysm.

3. Negative pregnancy test (serum or urine) in a female subject who has had menses in the last 18 months.

4. Subject commits to return to the investigational site for the 30- day, 6-month, 12-month, 2-year, 3-year, and 5-year follow-up evaluations.

5. The subject or his/her authorized representative must sign the IRB-approved written informed consent form prior to the start of any study procedures.

6. The subject has a modified Rankin Scale (mRS) = 2.

7. The subject has a wide-necked ( =4mm or dome-to-neck ratio <2) saccular or fusiform aneurysm.

Exclusion Criteria:

Subjects shall be excluded from the study if ANY of the following conditions exist:

1. Subject who suffers from a subarachnoid hemorrhage in the last 60 days.

2. Subject who suffers from intracranial hemorrhage in the last 30 days.

3. Subject who presents with an intracranial mass or currently undergoing radiation therapy for carcinoma of the head or neck region.

4. Subject with symptomatic extracranial or intracranial stenosis of the parent artery (>50%) proximal to the target aneurysm.

5. Subject with an irreversible bleeding disorder, a platelet count < 100 x 103 cells/mm3 or known platelet dysfunction or a contraindication to or inability to tolerate anticoagulants/antiplatelet agents or thrombolytic drugs.

6. Subject with history of major bleeding disorder (based on coagulation profile and platelet count) and/or subject presents with signs of active bleeding.

7. Subject with known hypersensitivity to any component of the treatment device that cannot be medically controlled.

8. Subject with documented contrast allergy, or other condition that prohibits imaging.

9. Evidence of active bacterial infection at the time of treatment.

10. Presence of any of the following unequivocal cardiac sources of embolism: chronic or paroxysmal atrial fibrillation, mitral stenosis, mechanical valve, endocarditis, intracardiac clot or vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, left atrial spontaneous echo contrast, ejection fraction less than 30%.

11. Subject with a pre-existing stent in place at the target aneurysm.

12. Subject who is unable to complete the required follow-ups.

13. Subject who is pregnant, breastfeeding, or of childbearing potential and unwilling to prevent pregnancy during their participation in the study.

14. Subject has a serious or life-threatening comorbidity that could confound study results and/or prevent completion of 5-year followup.

15. Subject is enrolled in another device or drug study in which participation could confound study results.

16. Subject has absent femoral pulses or other condition preventing femoral access, or is planned to be treated using a radial access approach.

Related Conditions & MeSH terms

• Aneurysm
• Intracranial Aneurysm

Intervention

Device:
• FRED™ X™
The FRED™ X™ System is indicated for use in the internal carotid artery from the petrous segment to the terminus for the endovascular treatment.

Locations

Country	Name	City	State
United States	Albany Medical Center	Albany	New York
United States	University of Maryland	Baltimore	Maryland
United States	Massachusetts General Brigham Incorporated	Boston	Massachusetts
United States	Montefiore Medical Center	Bronx	New York
United States	University at Buffalo	Buffalo	New York
United States	Ohio Health Riverside Research Institute	Columbus	Ohio
United States	Ohio State University	Columbus	Ohio
United States	Memorial Healthcare Systems	Hollywood	Florida
United States	University of Iowa	Iowa City	Iowa
United States	University of Kansas	Kansas City	Kansas
United States	Baptist Healthcare System	Louisville	Kentucky
United States	Norton Healthcare	Louisville	Kentucky
United States	Northwell Health	Manhasset	New York
United States	Ochsner Health	New Orleans	Louisiana
United States	University of Oklahoma Health Sciences Center	Oklahoma City	Oklahoma
United States	Orlando Health	Orlando	Florida
United States	Thomas Jefferson University	Philadelphia	Pennsylvania
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	Stony Brook University	Stony Brook	New York
United States	ProMedica Toledo Hospital	Toledo	Ohio
United States	UMass Memorial Health	Worcester	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Microvention-Terumo, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Safety Endpoint Part 1: Proportion of subjects that experience either Death or major stroke within 30 days post-procedure.	Major stroke is defined as a new neurological event that persists for >24 hours and results in a =4-point increase in the NIHSS score compared to baseline or compared to any subsequent lower score.	30-days
Primary	Primary Safety Endpoint Part 2: Proportion of subjects that experience neurological death or major ipsilateral stroke within 12 months post-procedure.	A major ipsilateral stroke is defined as that occurring within the vascular distribution of the stented artery. Neurological death is defined as a death which has been adjudicated by an independent clinical events committee to have directly resulted from a neurologic cause.	12 months
Primary	Primary Effectiveness Endpoint: The percent of subjects with (1) complete (100%) occlusion of the target aneurysm and =50% stenosis of the parent artery at the target IA, and (2) in whom an alternative treatment of the target IA had not been performed.	(1) Complete (100%) occlusion of the target aneurysm is assessed utilizing the Raymond-Roy Scale (Raymond Roy Class 1) and =50% stenosis of the parent artery at the target IA), and in whom an alternative treatment of the target IA had not been performed. The study will utilize independent Core Laboratory to adjudicate all angiographic outcomes, including aneurysm occlusion status and parent artery stenosis. (2) Alternative treatment is defined as re-treatment of the target aneurysm with an alternative treatment modality including open repair, endovascular placement of an additional stent or treatment of in-stent stenosis.	12 months